ReviewStem cell reviews and reports2026
The Role of Fibro/adipogenic Progenitors (FAPs) in Sarcopenia: Mechanisms and Potential Therapeutic Strategies.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sarcopenia is an age-related degenerative disease of skeletal muscles, characterized by progressively declined muscle mass, strength, and physical function. The prevalence of sarcopenia ranges from 11% to 50% among the global elderly population. The etiology of sarcopenia is multifactorial, including protein homeostasis imbalance, mitochondrial dysfunction, muscle satellite cells (MuSCs) dysfunction, chronic low-grade inflammation, and muscle interstitial remodeling. FAPs are mesenchymal-derived progenitor cells, playing crucial roles in maintaining muscle homeostasis and in the progression of sarcopenia. Under physiological conditions, FAPs interact with MuSCs and immune cells through their paracrine functions, providing supportive microenvironment for the growth and maintenance of muscle cells and MuSCs. Conversely, under pathological conditions, the abnormally activated and differentiated FAPs generated excessive intramuscular fat and fibrous tissue, which exacerbate the loss of muscle mass and strength in sarcopenia patients. The fate of FAPs are regulated by a complex signaling network composed by multiple pathways such as Wnt, Notch, and TGF-β/Smad, the dysregulation of which significantly contributes to the pathological differentiation of FAPs. Recently, single-cell sequencing technology have facilitated the identification of various FAP subpopulations, and provides new insights into the role of FAPs in sarcopenia. However, there are no specific therapeutic drugs for sarcopenia. Targeting molecules that govern FAP fate or eliminating dysfunctional FAP subpopulations represents a promising therapeutic strategy. Our review discusses the current understanding of sarcopenia and the role of FAPs in sarcopenia, and summarizes several novel therapeutic strategies targeting FAPs for the treatment of sarcopenia.
Indexed as
Identifiers
41491250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.